Quarterly report pursuant to Section 13 or 15(d)

ACCRUED EXPENSES

v3.21.2
ACCRUED EXPENSES
 9 Months Ended
Sep. 30, 2021
Payables and Accruals [Abstract]  
ACCRUED EXPENSES

10. ACCRUED EXPENSES

 

Accrued expenses consisted of the following:

 

 

 

September 30,
2021

 

 

December 31,
2020

 

 

 

 

 

 

 

 

Accrued clinical operations and trials costs

 

$

8,431,267

 

 

$

14,132,842

 

Accrued product development costs

 

 

240,648

 

 

 

2,189,047

 

Accrued compensation

 

 

3,337,362

 

 

 

4,222,594

 

Accrued other

 

 

1,358,856

 

 

 

1,460,949

 

Total

 

$

13,368,133

 

 

$

22,005,432